Home
SCYX
SCYX News

Latest SCYNEXIS Inc. (SCYX) News on December 26, 2024

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

GlobeNewswire

8 days ago

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

2 months ago

SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Associated Press Finance

2 months ago

Scynexis: Q3 Earnings Snapshot

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

2 months ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years

Simply Wall St.

2 months ago

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire

3 months ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

GuruFocus.com

3 months ago

Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

GlobeNewswire

3 months ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

4 months ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

SCYNEXIS Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

5 months ago

SCYNEXIS Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Associated Press Finance

5 months ago

Scynexis: Q2 Earnings Snapshot

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

5 months ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

GlobeNewswire

5 months ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

Associated Press Finance

8 months ago

Scynexis: Q1 Earnings Snapshot

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

8 months ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five years

Simply Wall St.

8 months ago

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five years

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

GlobeNewswire

8 months ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

GlobeNewswire

9 months ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire

9 months ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

GlobeNewswire

a year ago

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

GlobeNewswire

a year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

GuruFocus.com

a year ago

MetroCity Bankshares Inc Reports Mixed Results for Q4 and Full Year 2023

Associated Press Finance

a year ago

MetroCity: Q4 Earnings Snapshot

METROCITY BANKSHARES, INC. REPORTS EARNINGS FOR FOURTH QUARTER AND YEAR ENDED 2023

PR Newswire

a year ago

METROCITY BANKSHARES, INC. REPORTS EARNINGS FOR FOURTH QUARTER AND YEAR ENDED 2023

Mama’s Creations to Ring Nasdaq Closing Bell on Tuesday, January 23, 2024

GlobeNewswire

a year ago

Mama’s Creations to Ring Nasdaq Closing Bell on Tuesday, January 23, 2024

New research warns of emerging "AI Gap" between brands and consumers

PR Newswire

a year ago

New research warns of emerging "AI Gap" between brands and consumers

OFS Credit Company Provides December 2023 Net Asset Value Update

Business Wire

a year ago

OFS Credit Company Provides December 2023 Net Asset Value Update

Oil Prices Weighed Down by Massive Build in Fuel Inventories

Zacks

a year ago

Oil Prices Weighed Down by Massive Build in Fuel Inventories

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

GlobeNewswire

a year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

PLBY Group to Participate in the 2024 ICR Conference

GlobeNewswire

a year ago

PLBY Group to Participate in the 2024 ICR Conference

Electrovaya Begins Shipping Infinity-HV Battery Systems

ACCESSWIRE

a year ago

Electrovaya Begins Shipping Infinity-HV Battery Systems

Brightcove Appoints New CMO and CRO, Creates COO Position

Business Wire

a year ago

Brightcove Appoints New CMO and CRO, Creates COO Position

FVCBankcorp (FVCB) Soars 5.9%: Is Further Upside Left in the Stock?

Zacks

a year ago

FVCBankcorp (FVCB) Soars 5.9%: Is Further Upside Left in the Stock?

Syntec Optics Expands Thin-Film Technology with Gold Coating Capabilities (Nasdaq: OPTX)

GlobeNewswire

a year ago

Syntec Optics Expands Thin-Film Technology with Gold Coating Capabilities (Nasdaq: OPTX)

Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years ago

Simply Wall St.

a year ago

Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years ago

11 Cheapest Stocks With Biggest Upside

Insider Monkey

a year ago

11 Cheapest Stocks With Biggest Upside

Unlocking Financial Freedom: The Power of Flex CDs in Today's Economy

PR Newswire

a year ago

Unlocking Financial Freedom: The Power of Flex CDs in Today's Economy

5 Struggling Stocks to Buy at a Discount

Motley Fool

a year ago

5 Struggling Stocks to Buy at a Discount

Associated Press Finance

a year ago

Scynexis: Q3 Earnings Snapshot

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

GlobeNewswire

a year ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

CORRECTING AND REPLACING: NOVONIX Finalizes US$100 Million Grant Award from U.S. Department of Energy

GlobeNewswire

a year ago

CORRECTING AND REPLACING: NOVONIX Finalizes US$100 Million Grant Award from U.S. Department of Energy

Positive Signs As Multiple Insiders Buy Relmada Therapeutics Stock

Simply Wall St.

a year ago

Positive Signs As Multiple Insiders Buy Relmada Therapeutics Stock

Share on Social Networks: